How does MGRM's EPS trend compare to peers?

**Monogram Technologies Inc. (MGRM) exhibits a unique financial profile compared to its peers in the Health Care Equipment & Supplies industry**, as evidenced by its earnings per share (EPS) trend and the application of specific financial metrics. 1. **Monogram's EPS Trend**: - Monogram reported a net loss of $16.3 million in 2024, resulting in a basic and diluted loss per common share of $0.51. 2. **Comparison with Peers**: - To compare Monogram's EPS trend with peers, we should focus on peers in the same industry and sector. However, no results were found with the exact same financial criteria as Monogram. - Applying broader criteria to peers in the Health Care Equipment & Supplies industry, it is essential to note that a direct comparison is challenging due to the absence of detailed peer-specific EPS data. 3. **Financial Metrics Analysis**: - To assess Monogram's financial health and growth potential, we should consider the following metrics: - Revenue YoY Growth Rate > 10% - EPS YoY Growth Rate > 10% - Debt-to-Equity Ratio < 0.5 - Operating Margin > 15% - Net Margin > 10% - ROE > 15% - ROA > 10% - EPS < 0 - No results were found with these criteria applied, indicating that Monogram does not meet the specified financial metrics for a strong comparison with peers. 4. **Conclusion**: Monogram's EPS trend and financial metrics suggest that it is currently under pressure compared to peers in the industry. The company's focus on developing next-generation surgical robots and potential FDA clearances could impact its financial trajectory positively in the future. However, caution is warranted due to the current financial losses and the competitive landscape in the orthopedic devices market. In summary, Monogram's EPS trend and financial metrics do not currently align with the strongest performers in its industry, but its developmental prospects and strategic initiatives may influence its future financial standing.